MDG.WA
Medicalgorithmics S.A. [MDG.WA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
MDG.WA Stock Summary
Top 10 Correlated ETFs
MDG.WA
Top 10 Correlated Stocks
MDG.WA
In the News
MDG.WA Financial details
Company Rating
Neutral
Market Cap
258.77M
Income
1.04M
Revenue
49.12M
Book val./share
9.44
Cash/share
2.91
Dividend
-
Dividend %
-
Employees
122
Optionable
No
Shortable
Yes
Earnings
24 Apr 2024
P/E
260.48
Forward P/E
-
PEG
-25.98
P/S
6.15
P/B
2.88
P/C
8.96
P/FCF
-13.14
Quick Ratio
2.9
Current Ratio
4.74
Debt / Equity
0.07
LT Debt / Equity
0.02
-
-
EPS (TTM)
0.11
EPS next Y
-
EPS next Q
-
EPS this Y
-107.98%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-4.54%
Revenue last 5Y
-20.65%
Revenue Q/Q
-1.43%
EPS Q/Q
-85.08%
-
-
-
-
SMA20
-3.7%
SMA50
-13.33%
SMA100
-3.7%
Inst Own
-
Inst Trans
-
ROA
1%
ROE
1%
ROC
0.06%
Gross Margin
84%
Oper. Margin
14%
Profit Margin
2%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
15.02-46.8
52W High
-43.35%
52W Low
+73.73%
RSI
37
Rel Volume
1.2
Avg Volume
14.67K
Volume
17.64K
Perf Week
-2.32%
Perf Month
-6.76%
Perf Quarter
-5.24%
Perf Half Y
-22.9%
-
-
-
-
Beta
0.513
-
-
Volatility
0.43%, 0.97%
Prev Close
3.82%
Price
26.06
Change
3.66%
MDG.WA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 55.28 | 48.2 | 27 | 26.51 | 11 | |
| Net income per share | 4 | -0.08 | -6.69 | -39.73 | 3.17 | |
| Operating cash flow per share | 12.26 | 3.74 | -0.96 | -1.42 | 1.11 | |
| Free cash flow per share | 10.48 | 1.32 | -2.17 | -4.92 | -1.06 | |
| Cash per share | 18.33 | 3.09 | 3.91 | 2.57 | 4.59 | |
| Book value per share | 52.64 | 54.29 | 50.11 | 10.42 | 14.04 | |
| Tangible book value per share | 5.63 | 4.16 | 1.35 | -0.7 | 2.83 | |
| Share holders equity per share | 52.64 | 54.29 | 50.11 | 10.42 | 14.04 | |
| Interest debt per share | 19.33 | 11.75 | 9.75 | 2.32 | 0.79 | |
| Market cap | 95.22M | 57.5M | 93.93M | 86.12M | 69.89M | |
| Enterprise value | 101.24M | 86.66M | 117.12M | 84.1M | 43.74M | |
| P/E ratio | 6.61 | -192.29 | -3.39 | -0.48 | 3.86 | |
| Price to sales ratio | 0.48 | 0.33 | 0.84 | 0.71 | 1.11 | |
| POCF ratio | 2.15 | 4.26 | -23.74 | -13.29 | 11.04 | |
| PFCF ratio | 2.52 | 12.09 | -10.48 | -3.85 | -11.57 | |
| P/B Ratio | 0.5 | 0.29 | 0.45 | 1.82 | 0.87 | |
| PTB ratio | 0.5 | 0.29 | 0.45 | 1.82 | 0.87 | |
| EV to sales | 0.51 | 0.5 | 1.05 | 0.7 | 0.7 | |
| Enterprise value over EBITDA | 2.7 | 4.67 | -5.86 | -1.14 | 2.06 | |
| EV to operating cash flow | 2.29 | 6.42 | -29.61 | -12.98 | 6.91 | |
| EV to free cash flow | 2.68 | 18.23 | -13.07 | -3.76 | -7.24 | |
| Earnings yield | 0.15 | -0.01 | -0.29 | -2.1 | 0.26 | |
| Free cash flow yield | 0.4 | 0.08 | -0.1 | -0.26 | -0.09 | |
| Debt to equity | 0.35 | 0.21 | 0.19 | 0.2 | 0.05 | |
| Debt to assets | 0.21 | 0.14 | 0.14 | 0.08 | 0.04 | |
| Net debt to EBITDA | 0.16 | 1.57 | -1.16 | 0.03 | -1.23 | |
| Current ratio | 1.23 | 1.3 | 1.1 | 0.91 | 3.69 | |
| Interest coverage | 7.04 | -0.07 | -35.91 | -4.96 | 63.51 | |
| Income quality | 2.33 | -45.15 | 0.14 | 0.04 | -0.21 | |
| Dividend Yield | 0.05 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0.36 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.12 | 0.18 | 0.26 | 0.26 | 0.08 | |
| Research and developement to revenue | 0 | 0.01 | 0.01 | 0.02 | 0.04 | |
| Intangibles to total assets | 0.67 | 0.74 | 0.71 | 0.44 | 0.59 | |
| Capex to operating cash flow | -0.15 | -0.65 | 1.27 | 2.45 | -1.95 | |
| Capex to revenue | -0.03 | -0.05 | -0.04 | -0.13 | -0.2 | |
| Capex to depreciation | -0.56 | -0.47 | -0.31 | -0.91 | -2.93 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 68.8 | 10.06 | 86.84 | 96.51 | 31.66 | |
| ROIC | 0.08 | 0 | -0.09 | -0.08 | 0.21 | |
| Return on tangible assets | 0.14 | 0 | -0.34 | -2.83 | 0.4 | |
| Graham Net | -4.05 | -8.43 | -10.42 | -8.23 | 1.35 | |
| Working capital | 16.85M | 8.49M | 3.6M | -3.51M | 31.19M | |
| Tangible asset value | 20.31M | 15M | 5.6M | -3.18M | 16.16M | |
| Net current asset value | 3.59M | -22.14M | -35.3M | -30.27M | 14.14M | |
| Invested capital | 0.35 | 0.21 | 0.19 | 0.2 | 0.05 | |
| Average receivables | 18.94M | 20.46M | 22.47M | 23.12M | 15.83M | |
| Average payables | 1.83M | 1.75M | 2.75M | 4.61M | 4.01M | |
| Average inventory | -18.94M | -9.14M | 1 | 0.5 | 4.39M | |
| Days sales outstanding | 33.46 | 47.53 | 72.88 | 72.42 | 45.09 | |
| Days payables outstanding | 58.09 | 90.6 | 147.2 | 285.13 | 66.54 | |
| Days of inventory on hand | -734.3 | 0 | 0 | 0 | 259.14 | |
| Receivables turnover | 10.91 | 7.68 | 5.01 | 5.04 | 8.09 | |
| Payables turnover | 6.28 | 4.03 | 2.48 | 1.28 | 5.49 | |
| Inventory turnover | -0.5 | 8.3M | 8.54M | 0 | 1.41 | |
| ROE | 0.08 | 0 | -0.13 | -3.81 | 0.23 | |
| Capex per share | -1.78 | -2.42 | -1.21 | -3.49 | -2.17 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 3.5 | 1.87 | 1.13 | 0.98 | 0.96 | |
| Net income per share | 0.93 | 0.09 | 0.15 | -0.12 | -0.02 | |
| Operating cash flow per share | 3.76 | -0.77 | 0.3 | -0.26 | 0.04 | |
| Free cash flow per share | 3.52 | -1.66 | 0.09 | -0.52 | -0.22 | |
| Cash per share | 2.57 | 2.63 | 3.92 | 3.34 | 2.91 | |
| Book value per share | 3.05 | 8.04 | 8.56 | 9.43 | 9.44 | |
| Tangible book value per share | 2.15 | 1.62 | 2 | 2.65 | 2.38 | |
| Share holders equity per share | 3.05 | 8.04 | 8.56 | 9.43 | 9.44 | |
| Interest debt per share | 1.15 | 0.43 | 0.8 | 0.24 | 0.65 | |
| Market cap | 34.23M | 122.02M | 164.62M | 231.9M | 296.09M | |
| Enterprise value | 23.08M | 95.86M | 133.51M | 198.62M | 272.49M | |
| P/E ratio | 1.85 | 32.52 | 27.09 | -46.68 | -415.86 | |
| Price to sales ratio | 1.96 | 6.57 | 14.58 | 23.89 | 30.95 | |
| POCF ratio | 1.83 | -15.92 | 54.28 | -90.06 | 755.34 | |
| PFCF ratio | 1.96 | -7.38 | 177.4 | -44.51 | -136.51 | |
| P/B Ratio | 2.26 | 1.52 | 1.93 | 2.47 | 3.15 | |
| PTB ratio | 2.26 | 1.52 | 1.93 | 2.47 | 3.15 | |
| EV to sales | 1.32 | 5.16 | 11.83 | 20.47 | 28.49 | |
| Enterprise value over EBITDA | 7.9 | 14.04 | 43.76 | -267.33 | 220.46 | |
| EV to operating cash flow | 1.23 | -12.5 | 44.02 | -77.14 | 695.14 | |
| EV to free cash flow | 1.32 | -5.8 | 143.87 | -38.12 | -125.63 | |
| Earnings yield | 0.14 | 0.01 | 0.01 | -0.01 | 0 | |
| Free cash flow yield | 0.51 | -0.14 | 0.01 | -0.02 | -0.01 | |
| Debt to equity | 0.36 | 0.05 | 0.09 | 0.03 | 0.07 | |
| Debt to assets | 0.15 | 0.04 | 0.07 | 0.02 | 0.05 | |
| Net debt to EBITDA | -3.82 | -3.83 | -10.2 | 44.78 | -19.09 | |
| Current ratio | 2.37 | 3.69 | 2.8 | 5.23 | 4.74 | |
| Interest coverage | 23.13 | 191.72 | 35.23 | -55.2 | -1.6 | |
| Income quality | 0.68 | 0.82 | 2 | 2.07 | -2.2 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.17 | 0.14 | 0.06 | 0.07 | 0.08 | |
| Research and developement to revenue | 0 | 0.03 | 0.05 | 0.07 | 0 | |
| Intangibles to total assets | 0.13 | 0.59 | 0.54 | 0.57 | 0.58 | |
| Capex to operating cash flow | -0.07 | 1.16 | -0.69 | 1.02 | -6.53 | |
| Capex to revenue | -0.07 | -0.48 | -0.19 | -0.27 | -0.27 | |
| Capex to depreciation | 0.35 | -7 | -2.43 | -5.56 | -3.65 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 7.98 | 4.13 | 5.42 | 5.15 | 1.95 | |
| ROIC | 0.23 | 0.03 | 0.02 | -0.01 | 0 | |
| Return on tangible assets | 0.15 | 0.02 | 0.03 | -0.02 | 0 | |
| Graham Net | 0.44 | 0.77 | 1.19 | 1.79 | 1.27 | |
| Working capital | 16.71M | 31.19M | 34.92M | 39.9M | 38.49M | |
| Tangible asset value | 10.7M | 16.16M | 19.91M | 26.41M | 23.71M | |
| Net current asset value | 8.44M | 14.14M | 18.15M | 24.38M | 21.12M | |
| Invested capital | 0.36 | 0.05 | 0.09 | 0.03 | 0.07 | |
| Average receivables | 4.88M | 7.43M | 6.55M | 5.61M | 6.67M | |
| Average payables | 5.75M | 2.41M | 1.92M | 1.62M | 1.98M | |
| Average inventory | 4.48M | 8.87M | 9.33M | 10.04M | 10.84M | |
| Days sales outstanding | 36.75 | 37.57 | 42.58 | 54.57 | 70.16 | |
| Days payables outstanding | 35.75 | 56.65 | 189.48 | 74.32 | 156.3 | |
| Days of inventory on hand | 124.46 | 220.62 | 1.19K | 456 | 778.24 | |
| Receivables turnover | 2.45 | 2.4 | 2.11 | 1.65 | 1.28 | |
| Payables turnover | 2.52 | 1.59 | 0.47 | 1.21 | 0.58 | |
| Inventory turnover | 0.72 | 0.41 | 0.08 | 0.2 | 0.12 | |
| ROE | 0.31 | 0.01 | 0.02 | -0.01 | 0 | |
| Capex per share | -0.25 | -0.89 | -0.21 | -0.26 | -0.26 |
MDG.WA Frequently Asked Questions
What is Medicalgorithmics S.A. stock symbol ?
Medicalgorithmics S.A. is a PL stock and trading under the symbol MDG.WA
What is Medicalgorithmics S.A. stock quote today ?
Medicalgorithmics S.A. stock price is $26.06 today.
Is Medicalgorithmics S.A. stock public?
Yes, Medicalgorithmics S.A. is a publicly traded company.
Company Profile
- Volume Average 14.67K
- Market Capitalization 258.77M
- Employee 122
- CEO Mr. Maciej Gamrot
- Headquarters Warsaw,PL
- IPO Date 2011-11-09
-
Website
https://www.medicalgorithmics.pl 
Medicalgorithmics S.A. provides cardiac diagnostic solutions in Poland, the United States, and internationally. The company offers PocketECG, a diagnostic solution for the diagnosis of arrhythmia that provides disclosure ECG signal, complete data, analysis, and comprehensive reporting; and PocketECG CRS for cardiac rehabilitation monitoring. It also provides ECG TechBot, a software using a set of algorithms for automatic analysis and interpretation of the ECG signal; PatchECG, a device enabling single-channel offline monitoring; and PocketECG IV that enables the PocketECG to be connected over the LTE band for continuous ECG signal transmission. In addition, the company offers information technology, biotechnology, ECG monitoring, and scientific research and development services; and manufactures and sells electro-medical equipment. Medicalgorithmics S.A. was founded in 2005 and is headquartered in Warsaw, Poland.
